Antidepressant use in pregnancy and persistent pulmonary hypertension of the newborn (PPHN): A systematic review

Reproductive Toxicology

Volumn 34, Issue 3, 2012, Pages 293-297

  't Jong, Geert W ^a   Einarson, Thomas ^a,b   Koren, Gideon ^a,b   Einarson, Adrienne ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Antidepressants; Persistent pulmonary hypertension of the newborn; Pregnancy

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; PAROXETINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

COHORT ANALYSIS; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; DRUG USE; ENVIRONMENTAL EXPOSURE; GESTATIONAL AGE; HUMAN; INFANT; MEDICAL RECORD REVIEW; NEWBORN; OUTCOME ASSESSMENT; PERSISTENT PULMONARY HYPERTENSION; PREGNANCY; PUBLICATION; PUERPERAL DEPRESSION; RETROSPECTIVE STUDY; REVIEW; RISK ASSESSMENT; SECOND TRIMESTER PREGNANCY; SYSTEMATIC REVIEW; THIRD TRIMESTER PREGNANCY;

ANTIDEPRESSIVE AGENTS; FEMALE; HUMANS; INFANT, NEWBORN; PERSISTENT FETAL CIRCULATION SYNDROME; PREGNANCY; SEROTONIN UPTAKE INHIBITORS;

EID: 84865557734     PISSN: 08906238     EISSN: 18731708     Source Type: Journal    
DOI: 10.1016/j.reprotox.2012.04.015     Document Type: Review

References (29)

1. Bennett H.A., Einarson A., Taddio A., Koren G., Einarson T.R. Prevalence of depression during pregnancy: systematic review. Obstetrics and Gynecology 2004, 103(4):698-709.
2. Alwan S., Reefhuis J., Rasmussen S.A., Friedman J.M. Patterns of antidepressant medication use among pregnant women in a United States population. Journal of Clinical Pharmacology 2011, 51(2):264-270.
3. Anon. WHO | Depression 2011, Available at: www.who.int/mental_health/management/depression/definition/en/ [accessed 20.10.11].
4. Lakshminrusimha S., Steinhorn R.H. Pulmonary vascular biology during neonatal transition. Clinics in Perinatology 1999, 26(3):601-619.
5. Dakshinamurti S. Pathophysiologic mechanisms of persistent pulmonary hypertension of the newborn. Pediatric Pulmonology 2005, 39(6):492-503.
6. Konduri G.G., Kim U.O. Advances in the diagnosis and management of persistent pulmonary hypertension of the newborn. Pediatric Clinics of North America 2009, 56(3):579-600. [table of contents].
7. Roofthooft M.T.R., Elema A., Bergman K.A., Berger R.M.F. Patient characteristics in persistent pulmonary hypertension of the newborn. Pulmonary Medicine 2011, 2011:858154.
8. Källén B., Olausson P.O. Maternal use of selective serotonin re-uptake inhibitors and persistent pulmonary hypertension of the newborn. Pharmacoepidemiology and Drug Safety 2008, 17(8):801-806.
9. Konduri G.G., Solimano A., Sokol G.M., Singer J., Ehrenkranz R.A., Singhal N., et al. A randomized trial of early versus standard inhaled nitric oxide therapy in term and near-term newborn infants with hypoxic respiratory failure. Pediatrics 2004, 113(3 Pt 1):559-564.
10. Silvani P., Camporesi A. Drug-induced pulmonary hypertension in newborns: a review. Current Vascular Pharmacology 2007, 5(2):129-133.
11. Fornaro E., Li D., Pan J., Belik J. Prenatal exposure to fluoxetine induces fetal pulmonary hypertension in the rat. American Journal of Respiratory and Critical Care Medicine 2007, 176(10):1035-1040.
12. Oberlander T.F., Warburton W., Misri S., Aghajanian J., Hertzman C. Effects of timing and duration of gestational exposure to serotonin reuptake inhibitor antidepressants: population-based study. British Journal of Psychiatry 2008, 192(5):338-343.
13. Hilli J., Heikkinen T., Rontu R., Lehtimäki T., Kishida I., Aklillu E., et al. MAO-A and COMT genotypes as possible regulators of perinatal serotonergic symptoms after in utero exposure to SSRIs. European Neuropsychopharmacology 2009, 19(5):363-370.
14. Ellfolk M., Malm H. Risks associated with in utero and lactation exposure to selective serotonin reuptake inhibitors (SSRIs). Reproductive Toxicology 2010, 30(2):249-260.
15. Downs S.H., Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. Journal of Epidemiology and Community Health 1998, 52(6):377-384.
16. Austin M.-P. To treat or not to treat: maternal depression, SSRI use in pregnancy and adverse neonatal effects. Psychological Medicine 2006, 36(12):1663-1670.
17. Koren G., Boucher N. Adverse effects in neonates exposed to SSRIs and SNRI in late gestation - Motherisk update 2008. Canadian Journal of Clinical Pharmacology 2009, 16(1):e66-e67.
18. Chambers C.D., Hernandez-Diaz S., Van Marter L.J., Werler M.M., Louik C., Jones K.L., et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. New England Journal of Medicine 2006, 354(6):579-587.
19. Reis M., Källén B. Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data. Psychological Medicine 2010, 40(10):1723-1733.
20. Andrade S.E., McPhillips H., Loren D., Raebel M.A., Lane K., Livingston J., et al. Antidepressant medication use and risk of persistent pulmonary hypertension of the newborn. Pharmacoepidemiology and Drug Safety 2009, 18(3):246-252.
21. Wichman C.L., Moore K.M., Lang T.R., St Sauver J.L., Heise R.H., Watson W.J. Congenital heart disease associated with selective serotonin reuptake inhibitor use during pregnancy. Mayo Clinic Proceedings 2009, 84(1):23-27.
22. Wilson K.L., Zelig C.M., Harvey J.P., Cunningham B.S., Dolinsky B.M., Napolitano P.G. Persistent pulmonary hypertension of the newborn is associated with mode of delivery and not with maternal use of selective serotonin reuptake inhibitors. American Journal of Perinatology 2011, 28(1):19-24.
23. Chambers C.D., Johnson K.A., Dick L.M., Felix R.J., Jones K.L. Birth outcomes in pregnant women taking fluoxetine. New England Journal of Medicine 1996, 335(14):1010-1015.
24. Shahin I., Einarson A. Knowledge transfer and translation: examining how teratogen information is disseminated. Birth Defects Research: Part A, Clinical and Molecular Teratology 2011, Available at: http://www.ncbi.nlm.nih.gov/pubmed/21948595 [accessed 27.10.11].
25. Einarson A., Schachtschneider A.K., Halil R., Bollano E., Koren G. SSRI'S and other antidepressant use during pregnancy and potential neonatal adverse effects: impact of a public health advisory and subsequent reports in the news media. BMC Pregnancy and Childbirth 2005, 5:11.
26. Kieler H., Artama M., Engeland A., Ericsson O., Furu K., Gissler M., et al. Selective serotonin reuptake inhibitors during pregnancy and risk of persistent pulmonary hypertension in the newborn: population based cohort study from the five Nordic countries. BMJ 2012, 344:d8012.
27. Girard I, Sommer C, Dahan S, Mitanchez D, Morville P. Risk factors for developing pneumothorax in full-term neonates with respiratory distress. Archives of Pediatrics, 2012 Feb 28.
28. Winovitch K.C., Padilla L., Ghamsary M., Lagrew D.C., Wing D.A. Persistent pulmonary hypertension of the newborn following elective cesarean delivery at term. Journal of Maternal-Fetal and Neonatal Medicine 2011, 24(11):1398-1402.
29. Belik J. Fetal and neonatal effects of maternal drug treatment for depression. Seminars in Perinatology 2008, 32(5):350-354.